Actively Recruiting
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
Led by University of Chicago · Updated on 2025-06-12
57
Participants Needed
1
Research Sites
189 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).
CONDITIONS
Official Title
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male participants aged 18 years or older
- Diagnosed with intermediate-risk prostate cancer meeting specific clinical and biopsy criteria
- No evidence of cancer spread outside the prostate on MRI or biopsy
- Chosen to receive focal therapy for prostate cancer treatment
- Confirmed non-metastatic prostate cancer based on standard imaging within 6 months before enrollment (for unfavorable intermediate-risk cases)
- Life expectancy of at least 10 years as assessed by the investigator
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less or Karnofsky score of 60% or higher
- Fit to undergo general anesthesia and focal therapy surgical procedure with adequate imaging visualization and tolerance for positioning
- Adequate organ and marrow function based on specified blood test thresholds
- Prior or concurrent malignancies allowed if they do not interfere with study assessments
- Agreement to use effective contraception during treatment and for 3 months after last ADT dose if sexually active with a woman of childbearing potential
- Ability to understand and sign informed consent
You will not qualify if you...
- Prior or current prostate cancer therapies such as biologic agents, chemotherapy, hormone therapy, radiotherapy, or surgery
- Pelvic radiation, chemotherapy, or immunotherapy for other cancers within 6 months before enrollment
- Locally advanced, nodal, or metastatic prostate cancer
- Unfit for pelvic MRI scanning due to claustrophobia, pacemaker, metallic implants, or contrast allergy
- Allergy or intolerance to study drug components
- History of bilateral orchiectomy
- Uncontrolled or major debilitating illnesses
- Receiving or recently received other investigational agents unless approved by the principal investigator
- Judged unsuitable for study participation or unlikely to comply with procedures by the investigator or principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UChicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
C
Cancer Intake
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here